1-10 of 10
Richard L. Wahl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Mark R. Litzow, George Chen, Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Camille N. Abboud, Nebu Koshy, Ben K. Tomlinson, Sunil Abhyankar, James M. Foran, Sameem Abedin, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Joanna Jamieson, Margarida Magalhaes-Silverman, Koen Van Besien, Michael W. Schuster, Arjun D. Law, Sebastian A. Mayer, Hillard M. Lazarus, Eugene Leung, Ming-Kai Chen, Mona Natwa, Jennifer Spross, Kate L Li, Norman Nagl, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Brenda M. Sandmaier, John Pagel, Sergio A. Giralt, Avinash Desai, Richard L. Wahl, Neeta Pandit-Taskar, Patrik Brodin, Patrick J. Stiff
Journal: Blood
Blood (2023) 142 (Supplement 1): 3529.
https://doi.org/10.1182/blood-2023-189040
Published: 2023
Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy Using Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33) in Combination with Low-Dose Cytarabine (LDAC) for Older Patients with Untreated Acute Myeloid Leukemia (AML)

Joseph G Jurcic, MD, Farhad Ravandi, MD, John M. Pagel, MD PhD, Jae H Park, MD, B. Douglas Smith, MD, Dan Douer, MD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, Richard L. Wahl, MD, Dennis Earle, Dragan Cicic, MD, David A. Scheinberg, MD PhD
Journal: Blood
Blood (2014) 124 (21): 5293.
https://doi.org/10.1182/blood.V124.21.5293.5293
Published: 2014
Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC
Journal: Blood
Blood (2010) 116 (21): 4916.
https://doi.org/10.1182/blood.V116.21.4916.4916
Published: 2010
Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose
Journal: Blood
Blood (2010) 116 (21): 3960.
https://doi.org/10.1182/blood.V116.21.3960.3960
Published: 2010
Journal Articles

Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results.

Mark S. Kaminski, MD, Melissa Tuck, MS, Judith Estes, BSN, MSN, Arne Kolstad, MD, PhD, Charles Warren Ross, MD, Denise Regan, BS, Thierry Horner, PhD, Vanessa C. Williams, MS, Tina Vleisides, DC, Richard L. Wahl, MD
Journal: Blood
Blood (2009) 114 (22): 3759.
https://doi.org/10.1182/blood.V114.22.3759.3759
Published: 2009
Journal Articles

Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin’s Lymphoma: Feasibility and Initial Safety

Heather A. Jacene, Yvette L. Kasamon, Richard F. Ambinder, Wayne Kasecamp, Donna Serena, Richard L. Wahl
Journal: Blood
Blood (2008) 112 (11): 3059.
https://doi.org/10.1182/blood.V112.11.3059.3059
Published: 2008
Journal Articles

Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy.

Yvette L. Kasamon, Richard L. Wahl, Harvey A. Ziessman, Caroline Fidyk, Kathryn Rogers, Genea Smith, Richard J. Jones, Richard F. Ambinder, Lode J. Swinnen
Journal: Blood
Blood (2007) 110 (11): 1894.
https://doi.org/10.1182/blood.V110.11.1894.1894
Published: 2007
Journal Articles

Dose Finding Trial of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Ian W. Flinn, MD, Ph D., Brad S. Kahl, MD, Eric Frey, Ph D, Jesus A. Bianco, MD, Richard J. Hammes, R Ph, Lynn S. Billing, Lode J. Swinnen, MD, George Sgouros, Ph D, Richard L. Wahl, MD
Journal: Blood
Blood (2004) 104 (11): 897.
https://doi.org/10.1182/blood.V104.11.897.897
Published: 2004
Journal Articles

Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Stewart Kroll, PhD, Richard L. Wahl, MD, Susan J. Knox, MD, Julie M. Vose, MD.
Journal: Blood
Blood (2004) 104 (11): 2631.
https://doi.org/10.1182/blood.V104.11.2631.2631
Published: 2004
Journal Articles

Radioimmunotherapy with iodine 131 I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

Clinical Trials & Observations
Mark S. Kaminski, Judith Estes, Kenneth R. Zasadny, Isaac R. Francis, Charles W. Ross, Melissa Tuck, Denise Regan, Susan Fisher, Jeanne Gutierrez, Stewart Kroll, Robert Stagg, George Tidmarsh, Richard L. Wahl
Journal: Blood
Blood (2000) 96 (4): 1259–1266.
https://doi.org/10.1182/blood.V96.4.1259
Published: 2000